Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURY 3: PG324 vs GANFORT in Glaucoma and Ocular Hypertension
NCT03284853Phase 3Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of netarsudil, latanoprost ophthalmic solution 0.005% (TearClear TC-002) in open-angle glaucoma (OAG), ocular hypertension, sponsored by Aerie Pharmaceuticals. Started Sep 2017; status: completed.
02
Drugs
netarsudillatanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03284853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284853.